Future Fund LLC Purchases 6,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Future Fund LLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 58.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 17,596 shares of the biopharmaceutical company’s stock after buying an additional 6,500 shares during the quarter. Halozyme Therapeutics comprises about 2.4% of Future Fund LLC’s investment portfolio, making the stock its 20th largest position. Future Fund LLC’s holdings in Halozyme Therapeutics were worth $841,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after acquiring an additional 30,901 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock valued at $85,254,000 after acquiring an additional 9,780 shares in the last quarter. Boston Trust Walden Corp grew its holdings in shares of Halozyme Therapeutics by 28.0% during the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after acquiring an additional 191,465 shares during the period. Victory Capital Management Inc. raised its position in shares of Halozyme Therapeutics by 60.0% in the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock worth $31,112,000 after acquiring an additional 243,940 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Halozyme Therapeutics by 6.2% in the 3rd quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after purchasing an additional 31,871 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares of the company’s stock, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares in the company, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,697 shares of company stock worth $1,754,451. Company insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on HALO. Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday. Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Up 1.4 %

NASDAQ:HALO opened at $60.98 on Monday. The firm has a 50-day simple moving average of $55.70 and a two-hundred day simple moving average of $54.73. The firm has a market cap of $7.51 billion, a P/E ratio of 17.78, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.